Heron Therapeutics (HRTX) Equity Ratio: 2010-2025
Historic Equity Ratio for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to 0.06.
- Heron Therapeutics' Equity Ratio rose 133.00% to 0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06, marking a year-over-year increase of 133.00%. This contributed to the annual value of -0.14 for FY2024, which is 5.47% up from last year.
- As of Q3 2025, Heron Therapeutics' Equity Ratio stood at 0.06, which was up 150.91% from -0.12 recorded in Q2 2025.
- Heron Therapeutics' 5-year Equity Ratio high stood at 0.63 for Q1 2021, and its period low was -0.20 during Q2 2023.
- In the last 3 years, Heron Therapeutics' Equity Ratio had a median value of -0.14 in 2024 and averaged -0.12.
- As far as peak fluctuations go, Heron Therapeutics' Equity Ratio slumped by 382.32% in 2023, and later surged by 133.00% in 2025.
- Over the past 5 years, Heron Therapeutics' Equity Ratio (Quarterly) stood at 0.25 in 2021, then slumped by 78.69% to 0.05 in 2022, then tumbled by 382.32% to -0.15 in 2023, then increased by 5.47% to -0.14 in 2024, then spiked by 133.00% to 0.06 in 2025.
- Its Equity Ratio stands at 0.06 for Q3 2025, versus -0.12 for Q2 2025 and -0.12 for Q1 2025.